Do autoantibodies shape cancer immunosurveillance?Show others and affiliations
2026 (English)In: Cell, ISSN 0092-8674, E-ISSN 1097-4172, Vol. 189, no 15, p. 4525-4530Article in journal, Editorial material (Other academic) Published
Abstract [en]
Why cancer arises, progresses, or proves fatal in some people but not others remains largely unresolved. Antibody repertoires, including autoantibodies targeting immune pathways, may shape cancer immunosurveillance. Mapping antibody landscapes across cancer-free, at-risk, and cancer-affected individuals could clarify their roles in cancer susceptibility and disease outcome.
Place, publisher, year, edition, pages
Cell Press, 2026. Vol. 189, no 15, p. 4525-4530
National Category
Cancer and Oncology Immunology in the Medical Area
Identifiers
URN: urn:nbn:se:uu:diva-595653DOI: 10.1016/j.cell.2026.06.021ISI: 001834928300001PubMedID: 42492493Scopus ID: 2-s2.0-105045033136OAI: oai:DiVA.org:uu-595653DiVA, id: diva2:2093694
2026-08-192026-08-192026-08-19Bibliographically approved